Clinical trials recruiting for Hormone Receptor Positive Breast Carcinoma
13
Recruiting trials
43
US states with sites
21
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Abemaciclib | 2 |
| ARX788 | 1 |
| AVA6103 | 1 |
| Amiloride | 1 |
| Anastrozole | 1 |
| Anti-Diarrheal Agent | 1 |
| Aromatase Inhibition Therapy | 1 |
| BGB-43395 | 1 |
| CDK4/6i plus ET | 1 |
| Cyclophosphamide | 1 |
| Doxorubicin | 1 |
| Durvalumab | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 5 |
| California | 4 |
| Massachusetts | 3 |
| Michigan | 3 |
| Ohio | 3 |
| Texas | 3 |
| Colorado | 2 |
| Georgia | 2 |
| Indiana | 2 |
| Kansas | 2 |
| Missouri | 2 |
| New York | 2 |
Top cities
Boston, Massachusetts 3Columbus, Ohio 3Atlanta, Georgia 2Denver, Colorado 2Detroit, Michigan 2Duarte, California 2Grand Rapids, Michigan 2Houston, Texas 2Irvine, California 2Irving, Texas 2
Self-screener
Recruiting trials
- 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
- ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
- AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
- Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia
- The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
- Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Related conditions
Trials recruiting for Hormone Receptor Positive Breast Carcinoma often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Anatomic Stage III Breast Cancer AJCC v8 39Anatomic Stage II Breast Cancer AJCC v8 35Hormone Receptor Positive Breast Cancer 24HER2 Negative Breast Carcinoma 15Anatomic Stage I Breast Cancer AJCC v8 30Metastatic Breast Carcinoma 23Metastatic breast cancer 131Hormone Receptor Positive HER-2 Negative Breast Cancer 8HER2-negative Breast Cancer 57
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Hormone Receptor Positive Breast Carcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.